ABSTRACT
INTRODUCTION S
ECOND-GENERATION, or atypical, antipsychotic medications have been shown, in adult studies, to demonstrate improved efficacy and side-effect profiles, compared to older neuroleptic agents (Lohr and Braff 2003) . Specifically, in adult studies, second-generation antipsychotics are shown to be effective in the treatment of refractory and negative-symptom schizophrenia, with reportedly less of a risk of extrapyramidal signs (EPS) or untoward endocrine effects (Collaborative Working Group 1998; Caroff et al. 2002) . Second-generation antipsychotics are being increasingly used in children and adolescents, despite limited research in this age group. Common pediatric uses include the treatment of psychosis, Tourette's Disorder, pervasive developmental disorders (PDD), bipolar disorder, and mental retardation. Additional uses target clinically significant symptom clusters, such as aggression, self-injury, and impulsivity.
In spite of the increasingly widespread pediatric use of second-generation antipsychotics, scientific evidence of efficacy and safety in children and adolescents is limited. Several prior reviews have examined the clinical use of atypical antipsychotics in children Campbell et al. 1999; Findling et al. 2000a; . We present an updated review of the most recent literature in children and adolescents, including studies of recently released agents. The particular focus of this study is an assessment of the existing pediatric evidence for the efficacy and safety of secondgeneration antipsychotic medications.
METHOD
We conducted an English language MED-LINE search of key words-atypical antipsychotics and children, toxicity, clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole, to identify published literature on the pediatric use of second-generation antipsychotics. Individual drug manufacturers were contacted to identify additional, but unpublished, data. Drug efficacy was assessed based on studies reporting specific outcome data on numbers of subjects with clinical improvement. Because different efficacy measures were used across studies, positive responders were identified according to the criteria used in each individual study. Side-effect percentages for each agent were calculated by dividing the number of subjects with a reported side effect by the total number of subjects in whom side effects data were available.
RESULTS
We identified 176 reports, including 15 double-blind, controlled trials, 58 open-label trials, 18 retrospective chart reviews, and 85 case reports/series (Fig. 1 ). There were 76 reports of risperidone, 37 reports of olanzapine, 24 reports of clozapine, 19 reports of quetiapine, 11 reports of ziprasidone, 3 reports of aripiprazole, and 6 miscellaneous studies comparing multiple second-generation agents. There were 11 double-blind, controlled studies of risperidone; 1 double-blind study comparing risperidone, olanzapine, and haloperidol, and 1 Birmaher ( double-blind, controlled trial each for clozapine, quetiapine, and ziprasidone. There were no controlled studies of aripiprazole. Identified reports include investigations of psychosis, bipolar disorder, PDD, Tourette's Disorder, mental retardation, conduct disorder, and severe attention deficit hyperactivity disorder (ADHD). Efficacy studies, safety studies, and anecdotal reports that assessed drug effectiveness are summarized in Table 1.  Table 2 lists single-case reports, or small-case series, that describe specific side effects or adverse events.
Percentages of subjects who experienced untoward effects with each medication are summarized in Table 3 . Only studies in which specific side-effect percentages were reported are included. The most frequently reported side effects were fatigue, cardiovascular changes, including orthostatic hypotension and tachycardia, increased appetite and weight gain, and hyperprolactinemia. The highest rates of cardiovascular effects were reported for clozapine (40%) followed by quetiapine (13%). A substantial percentage of subjects experienced fatigue or sedation, ranging from 20% for olanzapine to 54% for ziprasidone. Hyperprolactinemia was evident with ziprasidone (23%), olanzapine (8%), and risperidone (4%). Reports of EPS or akathisia were infrequent, but evident for each drug, with the highest percentage described with risperidone (12%). A summary comparison of relative sideeffect frequencies among second-generation medications is presented in Fig. 2 .
Clozapine
In 24 published reports of clozapine, we identified 7 open-label studies, 2 chart reviews, 14 case reports/series, and 1 doubleblind, controlled study. Most of these were published prior to 2000, suggesting that alternative agents have become more widely used. These reports suggest that clozapine treatment led to improvement in patients with childhood psychosis, bipolar disorder, treatment refractory schizophrenia, tardive dyskinesia, and aggression. The double-blind, controlled comparison found clozapine to 
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be superior to haloperidol in childhood schizophrenia on all positive and negative psychotic symptom measures (p = 0.04-0.002). However, one-third of the clozapine-treated group discontinued medication because of intolerability.
A pharmacokinetic study of clozapine was completed in 6 youths (aged 9-16 years) with schizophrenia (Frazier et al. 2003) . Serum was collected after 6 weeks of treatment prior to, and 30 minutes following, a morning dose of 3.4 mg/kg. The metabolite norclozapine was found to exceed clozapine in its concentration, in contrast to adults in whom the opposite is true. Dose-normalized concentrations of clozapine did not vary with age and were similar to adults.
Increased risk for agranulocytosis has been the most significant limiting factor in clozapine use. Alvir et al. (1993) reviewed data on 11,555 clozapine-treated patients and found that increased risk was associated with increased age and female sex, although rates of agranulocytosis were somewhat higher in patients under age 21 years, compared to those aged 21-40 years. The cumulative incidence was 0.8% at 6 months and 0.9% at 18 months (Alvir et al. 1993) . We found reports of agranulocytosis for 2 (0.1%) of 243 clozapine-treated patients, suggesting levels of risk in children and adolescents consistent with, or less than, the overall population.
Among second-generation antipsychotics, clozapine is most often associated with orthostatic hypotension in adult studies (Collaborative Working Group 1998). In our review, 12% of clozapine-treated subjects had orthostasis and 28% had tachycardia. Two cases of electrocardiogram (ECG) changes were identified without reference to specific changes (Remschmidt et al. 1994) .
Risperidone
There are 76 reports on risperidone, including 11 blinded, controlled studies. There are more reports and more double-blind, controlled studies of risperidone than for any other second-generation antipsychotic. Anecdotal reports and open-label studies support a role for risperidone in the treatment of childhood psychosis, mania, tic disorders, PDD, aggression, disruptive behavior, eating disorders, and a variety of treatment-resistant conditions (Table 1) . The pharmacokinetics and safety of risperidone have been studied in 6 children with autism, in which derived parameters were consistent with extensively metabolizing adults (Casaer et al. 1994) .
There are no placebo-controlled studies of risperidone in pediatric psychosis, although 11 open reports suggest that many patients demonstrate measurable improvement. One randomized, double-blind study of 50 children (aged 8-19 years) with psychosis compared responses to risperidone (1-6 mg/d), haloperidol (2-8 mg/d), and olanzapine (5-20 mg/d), and reported positive response in 74% of those treated with risperidone, 88% with olanzapine, and 53% with haloperidol (Sikich et al. 2003) . Within subject improvement was significant for all agents, and rates and magnitude of response across all three agents were comparable. However, youth treated with secondgeneration agents experienced more weight gain and EPS than expected from adult studies.
In a small, double-blind comparison with clonidine for Tourette's Syndrome, both treatments showed improvement, without a discernable difference between the two agents (Gaffney et al. 2002) . In a second controlled study, 68% of risperidone-treated subjects versus 26% of the placebo group had significant improvement, as measured by the Global Severity of the Tourette's Symptom Severity Scale (Dion et al. 2002) . Scahill et al. (2003) also found significant reductions in tic severity with risperidone, compared to placebo. Moderate-to-robust effects were noted in 7 additional placebo-controlled studies in aggression and disruptive behavior.
In an investigation of 101 children (aged 5-17 years) with autism, subjects were randomly assigned to risperidone or placebo for an initial 8-week, double-blind, randomized, placebo-controlled trial (McCracken et al. 2002) . Response was robust, with 69% of the active group versus 12% on placebo showing acute improvement (defined by a 25% reduction from baseline in Irritability score from the Aberrant Behavior Checklist and a rating of Much or Very Much Improved on the Clinical Global Impression Scale [CGI]). Two-thirds of children remained positive in response at 6 months. Lewis (1998) and Demb et al. (1999) suggested that children and adolescents might experience risperidone-related EPS at higher rates than adults. Two open-label studies of risperidone in PDD found no increased risk (Perry et al. 1997; McDougle et al. 1997) . Several reports described the development of withdrawal dyskinesias and tardive dyskine-384 CHENG ET AL.
sia (Feeney et al. 1996; Rowan et al. 1997; Carroll et al. 1999) . One report described risperidone-related neuroleptic malignant syndrome (NMS) (Robb et al. 2000) . Comparative risks for these untoward effects with adult patients are unknown. Prolactin levels in children treated with risperidone were reviewed, examining data from five studies (Findling et al. 2003a) . After a modest, early increase, mean serum prolactin levels decreased after 8 weeks of risperidone therapy. Levels were above baseline, but within normal, at the end of 1 year. Kumra et al. (1997) described 1 case of hepatotoxicity and recommended a routine monitoring of liver function tests, cholesterol, and triglycerides every 3 months during the maintenance treatment. Other investigators indicated that current data do not support this recommendation (Geller and Zuiderwijk 1998). Still others recommend that, until further studies are conducted, it is wise to monitor liver function tests in children taking risperidone, particularly in those who are obese or show rapid weight gain. (Landau and Martin 1998 ).
Several case reports described potential negative interactions with the coadministration of risperidone and other psychotropics. A 10-year-old boy developed toxic levels of valproic acid after the initiation of risperidone (Van Wattum 2001). A second report described a decrease in valproic acid levels (Bartoldo 2002). In a recent letter to the editor, it was proposed that longer-acting forms of valproic acid might be less likely to cause such interactions, based on a chart review done on 45 child and adolescent psychiatry inpatients started on divalproex sodium (Good et al. 2003 ). One additional report described the possible interaction between risperidone, clomipramine, and erythromycin in a 15-year-old child with multiple diagnoses (Fisman et al. 1996b ) who developed agitation, labile mood, and increased talking 24 hours after the addition of erythromycin to a risperidone-clomipramine regimen.
Olanzapine
We identified 37 olanzapine studies; 8 for psychosis, 4 for mania, 3 for tic disorders, 5 for PDD, 3 for eating disorders, 4 for other indications, and 10 small-case reports describing untoward events. There were no pediatric double-blind, controlled studies. Olanzapine was inferior to clozapine in 1 open-label comparison for pediatric psychosis, which found that 53% of clozapine versus 0% of olanzapine subjects responded after 6 weeks (Kumra et al. 1998) . Most open trials and anecdotal reports described improvement in a majority of subjects for the conditions studied, but the overall effectiveness of olanzapine is difficult to assess without placebo control groups.
There have been multiple reports of endocrine and gastrointestinal difficulties in pediatric subjects treated with olanzapine. A recent report showed that mean and peak hepatic enzyme levels were significantly higher for 12 children treated with combination olanzapine and divalproex, compared to olanzapine and divalproex monotherapy (Gonzalez-Heydrich et al. 2003a) . In most of these cases, the hepatic enzyme elevations were less than 3 times the upper limit of normal range, and were, therefore, not at the threshold for immediate concern. However, 2 patients were above this range, with the concomitant development of steatohepatitis in 1 patient and pancreatitis in the other patient. In a separate report, 9 adolescents developed hyperglycemia on 10-20 mg/day, of whom 4 adolescents regained glycemic control after discontinuation, while 1 adolescent died from a necrotizing pancreatitis (Koller et al. 2001 ). A third report described 2 youths who developed diabetes and 3 youths with glucose dysregulation following olanzapine treatment (Bloch et al. 2003) .
Exposure to a high dose of olanzapine at 80 mg/day was without observed side effects (Heimann et al. 1999) . A reported overdose of 3-40 mg in an 18-month-old patient resulted in respiratory distress and mental status changes (Catalano et al. 1999) .
Quetiapine
There are 19 published studies of quetiapine. There are no pediatric double-blind, controlled studies of quetiapine monotherapy.
Case reports and open-label studies suggest good clinical improvement in the treatment of
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psychosis, disruptive behavior, mania, tic disorders, OCD, and PDD. In 1 blinded, controlled trial, quetiapine has shown promise as an adjunct to divalproex sodium (VPA) in the treatment of adolescent mania (DelBello et al. 2002) . Thirty manic, or mixed, bipolar I adolescents (12-18) were initially treated with VPA (20 mg/kg) and subsequently randomized to quetiapine at a mean dose of 432 mg/day (n = 15) or placebo (n = 15). The VPA-quetiapine group showed an 87% response rate, defined as a >50% reduction in baseline score on the Young Mania Rating Scale (YMRS), compared to a 53% response in VPA/placebo. Decreased thyroxine (T4) levels have been reported with quetiapine use, suggesting that clinical monitoring for signs of hypothyroidism is warranted (McConville et al. 2000; Shaw et al. 2001) . In animal studies, an association has been found between quetiapine and the development of cataracts (AstraZeneca, data on file). Although there is no association in humans, the manufacturer recommends eye examinations for evidence of cataracts prior to initiation and at 6-month treatment intervals. An 88-week, open-label study with 10 children and ending doses ranging from 300-800 mg/day showed minimal untoward events and a favorable long-term safety and tolerability (McConville et al. 2003) .
Ziprasidone
There were 11 published pediatric reports on ziprasidone. In the sole double-blind, placebo-controlled study, ziprasidone was superior to placebo in 28 patients treated for Tourette's Disorder . Mild somnolence was the most common adverse event. Ziprasidone was not associated with any weight gain and only caused transient increases in prolactin concentration. No ECG abnormalities were described, but the sample size was too small to assess safety risks adequately. Sallee et al. (2003) assessed the pharmacodynamic effects of ziprasidone in 24 children with Tourette's Syndrome or chronic tic disorder. Peak serum ziprasidone levels were achieved 4 hours following a single-dose, open-label administration, with a concomitant peak in serum prolactin. Peak eye-blink rates were observed 6 hours after dosing. These pediatric findings were judged to be consistent with adult pharmacodynamics, where ziprasidone is a direct dopamine antagonist and indirect dopamine agonist by way of 5-HT 2A agonism.
Aripiprazole
Three pediatric studies of aripiprazole were identified. An early report described shortterm safety and tolerability (Mallikaarjun et al. 2000) . Initial doses of 1 mg/kg/day titrated to a maximum of 15 mg/day were well tolerated. Aside from nausea and vomiting, no other adverse events, including negative cardiovascular outcomes, were reported.
The pharmacokinetic effects of aripiprazole in conduct disorder were studied in an openlabel study with 23 subjects (Findling et al. 2003c) . Oral clearance was similar in adolescents and adults, and the degree of accumulation was similar for children, adolescents, and adults. Both children and adults exhibited within subject improvement, as monitored by the Rating of Aggression Against People or Property (RAAPP) and CGI scale. The most frequently reported adverse events were somnolence, vomiting, increased appetite in children, and headache and dyspepsia in adolescents. Optimal dosing appears to be lower in children than in adults. A third report described the development of EPS in 1 aripiprazole-treated child (Lindsey et al. 2003) .
DISCUSSION
The evidence base for the pediatric use of second-generation antipsychotics is rapidly expanding, with over 40% of identified reports published from 2001 through 2003. Nonetheless, the majority of these reports are anecdotal, or open-label trials, with double-blind, controlled studies representing less than 9%. Surprisingly, the most equivocal evidence of efficacy is in the treatment of psychosis and schizophrenia. The paucity of positive, controlled studies for pediatric psychosis reflects the difficulties encountered in conducting this 386 CHENG ET AL.
research. The severity of pediatric psychosis limits the ethical use of placebo in controlled trials, while comparison studies with other neuroleptic agents requires large numbers of subjects and assumptions that comparator agents are efficacious. Growing evidence of efficacy in other conditions, such as tic disorders, autism, and aggression is more conclusive, although there is a continued need for large replication studies of preliminary positive findings. In the absence of well-controlled efficacy studies, the possibility remains that various agents might differentially effect various clinical indications. Certainly, these agents possess modest differences in receptor affinities, with aripiprazole possibly being the most distinct in presumed mechanism of action. Likewise, differences in mechanisms of action might relate to differences, apparent or occult, in adverse events. The well-recognized potential for long-term side effects, particularly tardive dyskinesia, with traditional neuroleptic agents created a conservative approach to medication that balanced the benefits and risks of treatment. There is a commonly held view that secondgeneration agents are safer than traditional neuroleptics. Our review of the pediatric literature, however, suggests that second-generation neuroleptics are associated with many of the same side effects seen with older compounds, such as EPS and hyperprolactinemia. Risperidone exhibits dose-related increases in prolactin nearly equivalent to first-generation agents. Similarly, Wudarsky et al. (1999) described moderate hyperprolactinemia with olanzapine and haloperidol, compared to transient increases within normal limits with clozapine. Second-generation neuroleptics are associated with other metabolic disturbances that have not been found with traditional agents. A 12-week naturalistic study of olanzapine, risperidone, and quetiapine in juveniles demonstrated significant weight gain, increased triglycerides, and insulin resistance for all compounds (Correll et al. 2003) .
Several potentially severe side effects have been associated with second-generation antipsychotics in adults. One report cites development of pancreatitis in 144 patients, 72 with clozapine, 62 with olanzapine, 32 with risperidone, and 12 with haloperidol (Koller et al. 2003) . Death occurred in 22 patients, but causality with medication could not be established. The absence of reports, or reports of other potentially fatal side effects, such as blood dyscrasias, in youth does not suggest an absence of risk, but indicates the need for well-monitored pediatric trials.
With or without published scientific trials, clinicians might determine that neuroleptic medications are useful in the treatment of individual patients. A greater concern than the lack of scientifically demonstrated efficacy lies in the absence of data on safety risks of longterm use. Emergent negative effects from acute treatment, particularly weight gain and endocrine abnormalities, cardiovascular changes, and sedation, are evident clinically and in published studies. Given the lack of long-term safety studies, potential risks from the sustained use of second-generation neuroleptics in children and adolescents are unknown. Virtually all pediatric use of these medications is "off-label," without an official Food and Drug Administration (FDA) indication.
Given the lack of safety information regarding these agents, we recommend following a systematic model for monitoring side effects in youth. Baseline assessment should include a full physical examination and review of systems, with special attention to seizures, pretreatment extrapyramidal signs, cardiac symptoms, and prolactin-associated phenomena, such as galactorrhea or amenorrhea. ECGs should be considered, particularly with ziprasidone, at baseline and upon reaching therapeutic dosage, with particular attention paid to changes in QTc interval (Gutgesell et al. 1999) . Consistent with recent FDA guidelines, weight, fasting glucose, and lipid levels should be assessed every 3 to 6 months. Concomitant prescription of other medications requires attention to possible drug interactions by way of the cytochrome P450 system. Standardized scales to assess EPS and other abnormal movements should be conducted before, and during, treatment and maintained in the medical record.
Our study has several limitations inherent in a literature review. Most information was derived from published reports. Open-label
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studies rarely report negative findings, and as such, our review might overestimate drug effectiveness. Similarly, our comparison of relative rates of side effects was based on available information in published literature. It is doubtful that side effects were assessed or reported consistently, and as such, our estimates are not likely to reflect rates that would be derived from systematic data collection in controlled studies. The lack of reported adverse events with newer agents, i.e., aripiprazole, does not imply these medications have better safety profiles, but reflects limited opportunities in data collection. Second-generation antipsychotics offer potential relief in many of the most severe pediatric behavioral disorders. Cautious use of these medications is warranted, provided reasonable measures are employed to monitor safety. Use of these agents will certainly increase. Additional short-and long-term studies are necessary to determine differential treatment effects and long-term risk in clinical practice. 
